10-K: Fortrea Reports 2025 Results: Goodwill Impairment Hits Earnings

Fortrea Holdings Inc. reports a significant net loss of $986.2 million in 2025, primarily driven by a substantial goodwill impairment charge, despite a slight revenue increase.

Summary

• Revenue for 2025 was $2,723.4 million, a 1.0% increase over $2,696.4 million in 2024, with organic revenue growth of 0.8% and favorable foreign currency translation of 0.2%.
• A net loss of $986.2 million was reported in 2025, significantly wider than the $328.5 million net loss in 2024.
• Operating loss widened to $872.6 million in 2025 from $161.9 million in 2024.
• A goodwill impairment charge of $797.9 million was recorded in 2025, specific to the Clinical Development reporting unit, with no such impairment in 2024.
• Direct costs increased by 2.7% to $2,219.6 million in 2025, representing 81.5% of revenues, up from 80.2% in 2024.
• Selling, general and administrative (SG&A) expenses decreased by 18.6% to $456.4 million in 2025 from $560.7 million in 2024.
• Interest expense decreased by 26.2% to $91.4 million in 2025, primarily due to debt paydowns.
• Cash flow from operating activities decreased to $113.5 million in 2025 from $262.8 million in 2024.
• The company's backlog stood at $7.7 billion as of December 31, 2025.
• One customer accounted for approximately 18.1% of revenue in 2025, and the top ten customers represented about 57% of total revenue and 54% of total backlog.
• Restructuring and other charges amounted to $44.1 million in 2025, down from $50.1 million in 2024.
• The Receivables Securitization Program was amended on February 24, 2026, extending its termination date to February 23, 2029, with $300.0 million of receivables sold as of December 31, 2025.
• A shareholder class action lawsuit was filed on June 2, 2025, alleging omissions and misrepresentations, with a motion to dismiss filed by the company on January 28, 2026.
• A stockholder rights plan was adopted on June 11, 2025, with rights expiring on June 10, 2026, designed to deter beneficial ownership of 10% or more of outstanding common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the substantial goodwill impairment and widening net loss, overshadowing modest revenue growth and operational efficiencies. The significant decrease in operating cash flow is also a concern.

Positives

• Revenue increased by 1.0% to $2,723.4 million in 2025, with 0.8% organic growth.
• Selling, general and administrative expenses decreased significantly by 18.6% to $456.4 million in 2025, driven by lower transition service agreement and information technology costs.
• Interest expense decreased by 26.2% to $91.4 million in 2025, attributed to debt paydowns of $70.2 million on term loan A and $412.5 million on term loan B.
• The company maintains a strong backlog of $7.7 billion as of December 31, 2025, providing future revenue visibility.
• Restructuring actions contributed to lower headcount and personnel costs, improving efficiencies.
• The Receivables Securitization Program was extended to February 23, 2029, enhancing liquidity management.
• Continued strategic investments are being made in artificial intelligence (AI), machine learning (ML), and other advanced technologies to improve speed, agility, quality, and patient safety in clinical research.
• Modernization of the Xcellerate platform and initial rollout of a CRA mobile app and digital assistant demonstrate technological progress.
• The company focuses on high-growth therapeutic areas, including oncology, central nervous system, metabolic disorders, immunology, rare diseases, and cell and gene therapies.
• Employee engagement survey results show consistent alignment with industry benchmarks and meaningful progress in collaboration, inclusion, and confidence in leadership.

Negatives

• A substantial net loss of $986.2 million was reported in 2025, significantly wider than the $328.5 million loss in 2024.
• A goodwill impairment charge of $797.9 million was recorded in 2025, primarily impacting the Clinical Development reporting unit.
• Operating loss widened to $872.6 million in 2025 from $161.9 million in 2024.
• Cash flow from operating activities decreased significantly to $113.5 million in 2025 from $262.8 million in 2024.
• Direct costs as a percentage of revenues increased to 81.5% in 2025 from 80.2% in 2024, driven by higher pass-through costs, stock compensation, reintroduction of variable compensation, and lower R&D tax credits.
• Foreign exchange loss increased by 153.8% to $26.9 million in 2025.
• Clinical development revenues were lower due to the mix of complex and longer-duration studies and reduced functional service provider revenue.
• A shareholder class action lawsuit was filed on June 2, 2025, alleging omissions and misrepresentations regarding securities laws.
• The effective tax rate was negative (0.3)% in 2025, influenced by goodwill impairment with no tax benefit and an increased valuation allowance.

Risks

• Inability to generate a large number of net new business awards, or if awards are delayed, terminated, or reduced in scope.
• Difficulty in contracting with suitable investigators and recruiting/enrolling patients for clinical trials.
• Additional risks and expenses associated with international operations, including compliance with foreign laws, currency fluctuations, and geopolitical tensions.
• Customer or therapeutic area concentrations could materially adversely affect business if large customers reduce or terminate relationships or if trials in a specific therapeutic class are canceled.
• Customers experiencing insufficient funding to complete their clinical trials, potentially requiring the company to incur costs without compensation.
• Backlog might not be indicative of future revenues, and anticipated revenue may not be fully realized due to cancellations, delays, or scope changes.
• Inability to attract and retain experienced and qualified personnel, including key management, and increased personnel costs.
• Dependence on third parties to provide services critical to the business, with risks if they fail to comply with laws or agreements.
• Failure to maintain effective internal controls, which could materially adversely affect business, financial condition, results of operations, and cash flows.
• Fluctuations in the effective income tax rate due to changes in tax legislation, earnings mix, or assessment of deferred tax assets.
• Failure to comply with regulations of pharmaceutical and medical device regulatory agencies (e.g., FDA, MHRA, EMA, NMPA, PMDA) could result in sanctions.
• Changes in government regulation or practices relating to the pharmaceutical, biotechnology, or medical device industries could decrease the need for certain services.
• Failure to comply with privacy and security laws and regulations (e.g., HIPAA, CCPA, CPRA, GDPR, DUA, DPDPA, PIPL) could result in fines, penalties, and reputational damage.
• Failure to comply with federal, state, and foreign laws and regulations, including healthcare fraud and abuse laws, anti-corruption laws (FCPA, U.K. Bribery Act), and trade sanction laws.
• Risks arising from the restructuring of operations, including service disruption, loss of key employees, and failure to achieve anticipated cost reductions.
• Failure to obtain, maintain, and enforce intellectual property rights or defend against challenges to intellectual property rights.
• Continuing contingent liabilities as a result of the spin-off from Labcorp, including potential indemnification liabilities.
• Financial risk for contracts that may be underpriced, subject to cost overruns, delayed, or terminated or reduced in scope.
• Revenues depend on R&D expenditures by the pharmaceutical, biotechnology, and medical device industries; any reductions or delays could materially and adversely affect the business.
• Foreign currency fluctuations and the planned use of financial instruments to limit exposure to currency fluctuations could expose the company to risks and financial losses.
• Costs associated with debt and debt covenant requirements may limit cash flow available to invest in the ongoing needs of the business.
• Inability to access the capital and credit markets on terms that are favorable or at all.
• The market price and trading volume of common stock may be volatile, and investors may lose all or part of their investments.
• The stockholder rights agreement could discourage, delay, or prevent a change in control.
• Anti-takeover provisions in charter documents and Delaware law could discourage, delay, or prevent a change in control.
• Investors' percentage of ownership may be diluted in the future due to equity issuances.
• No current plans to pay dividends, making stock price appreciation the sole driver of investment return.
• Actions of activist stockholders could impact the pursuit of business strategies, cause substantial costs, and divert management's attention.
• Failure to maintain the security of customer-related information or compliance with security requirements.
• Failure in IT systems, including hardware and software failures, delays, and inability to implement new systems or enhancements.
• Security breaches and unauthorized access to company or customer data.
• Failures of internally developed and licensed technology systems used to manage clinical trials.
• Failure to keep pace with rapid technological changes could make services less competitive or obsolete.
• Issues in the development, deployment, and/or use of AI may result in reputational harm, liability, regulatory action, or adversely affect business.
• Operations may be disrupted and adversely impacted by adverse weather, natural disasters, geopolitical events, public health crises, and other events outside of control.
• Increasing attention to sustainability-related matters may impose additional costs and expose the business to new risks.

Future Outlook

The company anticipates the Contract Research Organization (CRO) market will experience slower growth in the short term, with a return to higher growth rates in the longer term. R&D investment by large biopharmaceutical companies is projected to grow at approximately 4-5% CAGR over the period 2025-2030, and biotechnology funding is expected to stabilize at historical levels of solid investments in the medium to longer term. The company plans to continue selective investments in key therapeutic areas, business areas, and geographies to drive growth and improve operational efficiency, primarily funded by cash flow from operations. Management also expects to increase operating margin over time through disciplined pricing, managing business mix, and improving operational and SG&A efficiencies. The company is preparing for ongoing developments in privacy, data security, and artificial intelligence laws, which will require continuous assessment and adaptation.

Management Comments

• Our team of approximately 14,300 employees is able to conduct operations in approximately 100 countries and delivers comprehensive phase I – IV clinical trial management, clinical pharmacology, and consulting services for our customers.
• We believe we are strategically positioned to serve the pharmaceutical, biotechnology, and medical device industries.
• We believe that our commitment to continuous service and technology innovations combined with Fortrea’s tailored approach to serve both biotechnology and large biopharmaceutical companies and experience across more than 20 therapeutic areas enables us to continue to differentiate ourselves from peers in the CRO industry.
• We believe our broad customer base positions us at the forefront of innovation in healthcare and allows us to help our customers efficiently bring the best therapeutic solutions to patients.
• We believe that our focus and expertise across rapidly growing scientific areas provide us with advantages over our competitors.
• Fortrea believes we have the opportunity to increase our operating margin over time.
• We are committed to increasing the representation of patient populations within clinical trials, and developed a holistic strategy focused on partnering with customers, sites, investigators, and communities to address this commitment and support the diversity plans expected by global regulatory authorities.
• Fortrea believes that excellence in project management is foundational to the consistency of delivery for customers of all sizes and types.
• We are committed to making Fortrea an engaging place where talented professionals can grow and advance their careers.
• We believe our existing cash and cash flows generated from operations, plus existing credit facilities, will be sufficient to cover the needs of our current and planned operations for at least the next 12 months.

Industry Context

StockSavvy.ai notes that the CRO market is expected to experience slower short-term growth before returning to higher long-term rates, aligning with Fortrea's outlook. The industry continues to benefit from increasing R&D spend by pharmaceutical and biotechnology companies, projected at a 4-5% CAGR for large biopharma over 2025-2030, and expanding scope of CRO capabilities, including decentralized trials and complex therapies. Fortrea's strategic focus on high-growth therapeutic areas like oncology and cell/gene therapies positions it to capitalize on these trends, despite a recent slowdown in biotech funding. The company's emphasis on flexible delivery models (Full Service, FSP, Hybrid) addresses evolving customer needs for cost efficiency and adaptability in clinical trials.

Comparison to Industry Standards

• The company believes it is positioned to be more flexible and customer-focused than larger competitors while offering global scale that smaller competitors lack.
• The peer group for common stock performance comparison includes Charles River Laboratories Inc., ICON plc, Medpace Holdings, Inc., IQVIA Holdings Inc., and Thermo Fisher Scientific Inc., indicating these are considered industry benchmarks.
• Internal control over financial reporting was deemed effective as of December 31, 2025, based on criteria established in the COSO framework, which is an industry-recognized standard.
• Employee engagement survey results show consistent alignment with industry benchmarks and meaningful progress across key engagement drivers.

Management Changes

Corporate Governance

Legal Proceedings

• A purported shareholder class action complaint, Lucas Deslande v. Fortrea Holdings Inc., et al., No 1:25-sv-04630, was filed on June 2, 2025, in the U.S. District Court for the Southern District of New York, naming the company and certain current and former officers as defendants. The complaint alleges omissions and misrepresentations violating securities laws. Lead plaintiffs were appointed on September 3, 2025, and an amended complaint was filed on November 10, 2025. The company filed a motion to dismiss on January 28, 2026, and intends to vigorously defend itself.
• Legal expenses of $1.9 million, $2.2 million, and $0 million were recorded for the years ended December 31, 2025, 2024, and 2023, respectively, related to the settlement of legal matters initiated prior to the spin-off.
• Concessions and discounts totaling $12.5 million were provided to a customer ($3.8 million in 2024 and $8.7 million in 2023) as part of a multi-party solution to facilitate trials, due to dosing sequence errors by a third-party vendor not associated with the company. No related reductions of revenue occurred in 2025 as the agreed-upon amount had been satisfied.

Related Party Transactions

• Prior to the June 30, 2023 spin-off, Fortrea's financial statements included allocated expenses from Labcorp Holdings Inc. (Former Parent) for centralized functions such as legal, tax, treasury, IT, human resources, finance, and executive leadership.
• A Transition Services Agreement with Labcorp was in place for certain transitional services, which expired in full on June 30, 2025.
• Direct costs for 2023 included $48.8 million for services purchased from Labcorp for commercial contracts.
• Allocations of foreign exchange gain/loss from Labcorp's hedging activities were included in combined statements of operations prior to the separation.
• A special payment of $1,595.0 million was made to Former Parent (Labcorp) in 2023.
• Net transfers to Former Parent amounted to $135.4 million in 2023.
• The company's wholly-owned subsidiary, Fortrea Receivables LLC, conveys receivable balances to a wholly-owned, bankruptcy-remote special purpose entity (SPE) under the Receivables Securitization Program, which in turn may sell receivables to a third-party financial institution.
• Subordinated Loans are mentioned in the Transfer Agreement and Subordinated Loan Agreement, with payments of principal and interest potentially made to Originators (Affiliates).

Stakeholder Impact

• Shareholders: The significant net loss and goodwill impairment are likely to negatively impact share price and investor confidence. Anti-takeover provisions and the stockholder rights plan may limit shareholder influence over control. No dividends are planned in the foreseeable future, meaning returns depend solely on stock appreciation.
• Employees: Restructuring plans involve eliminating redundant positions, which could lead to job losses. However, investments in global early talent development, career paths, learning opportunities, and an inclusive culture aim to attract and retain talent.
• Customers: The company's focus on flexible delivery models, scientific expertise, and technology investments aims to provide enhanced value. However, project delays and cancellations can impact customer relationships and satisfaction.
• Suppliers/Vendors: Dependence on third-party service providers means their performance directly impacts Fortrea's ability to deliver services, potentially affecting supplier relationships if issues arise.
• Creditors: The company's aggregate principal indebtedness of approximately $1,066.3 million and associated debt covenants could limit cash flow available for business investment. A downgrade in credit ratings could increase borrowing costs.

Next Steps

• Increase brand awareness, identify new clients, and expand existing relationships to drive growth.
• Improve win-rates and leverage data, analytics, and AI-enabled tools for prospect identification and engagement.
• Upskill commercial and account management teams and increase senior management engagement with customers.
• Lead with scientific and therapeutic expertise, expanding in existing and novel high-growth therapeutic areas.
• Increase the utilization of clinical pharmacology units and expand wraparound services, optimizing complex hybrid study designs.
• Continue selective investment in technology, data, AI, ML, and workflow automation to accelerate trial execution and enhance quality.
• Scale the rollout and enhance features of the CRA mobile app and digital assistant.
• Become the partner of choice for pharmaceutical, biotechnology, and medical device companies of all sizes.
• Expand the small and mid-size customer base and build long-tenured partnerships, enhancing the biotech operating model.
• Continue to provide high levels of service and expand existing partnerships with large pharmaceutical customers, adding new partnerships where strategically aligned.
• Embed a disciplined, quality-centric approach to project management and increase access to training, tools, technology, and infrastructure.
• Continue investments in global early talent development, career paths, learning opportunities, Responsible People Practices Advisory Committee, and Employee Resource Groups.
• Monitor the effects of the Inflation Reduction Act and other regulatory developments on financial condition, operating results, and income tax rate.
• Continue to monitor the implementation of the OECD's Pillar Two Framework.
• Assess and adapt to ongoing privacy, data security, and artificial intelligence laws.
• Vigorously defend against the shareholder class action lawsuit.
• Make approximately $2.2 million in required contributions to defined benefit pension plans during 2026.

Key Dates

Recommendation

The significant goodwill impairment of $797.9 million, leading to a substantial net loss of $986.2 million, indicates severe challenges in the company's core Clinical Development reporting unit. Despite a slight revenue increase, the widening operating loss and a notable decrease in operating cash flow suggest underlying operational inefficiencies and financial strain. The ongoing shareholder class action lawsuit and increased foreign exchange losses add to the negative sentiment. While strategic investments and debt reduction are positive, the magnitude of the impairment and losses points to fundamental issues that warrant a cautious 'Sell' recommendation for seasoned investors.

Keywords

Contract Research Organization, Clinical Trials, Biopharmaceutical Development, Goodwill Impairment, Financial Performance, SEC Filing, 10-K Report, Clinical Development, Clinical Pharmacology, R&D Spend, Outsourcing, Corporate Governance, Risk Management, Debt, Shareholder Rights Plan, AI in Clinical Research, Regulatory Compliance, Fortrea Holdings Inc.